Compositions and methods

Patent metadata

Field	Value
Publication number	US-10286053-B2
Application number	US-201615266220-A
Country	US
Kind code	B2
Filing date	Sep 15, 2016
Priority date	Jul 25, 2008
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

First claim

We claim:

1. An immunogenic composition comprising:
(i) a polypeptide which comprises an immunogenic fragment of at least 9 contiguous amino acids from an Rv2386c protein selected from the group consisting of SEQ ID NOs: 1 and 6; and
(ii) a non-specific immune response enhancer.

2. The immunogenic composition according to claim 1 , wherein the polypeptide comprises an immunogenic fragment of at least 9 contiguous amino acids from the Rv2386c protein of SEQ ID NO: 1.

3. The immunogenic composition according to claim 2 , wherein the polypeptide comprises an immunogenic fragment of at least 20 contiguous amino acids from the Rv2386c protein of SEQ ID NO: 1.

4. The immunogenic composition according to claim 3 , wherein the polypeptide comprises an immunogenic fragment of at least 50 contiguous amino acids from the Rv2386c protein of SEQ ID NO: 1.

5. A method for eliciting an immune response in a subject comprising the administration of a polypeptide which comprises an immunogenic fragment of at least 9 contiguous amino acids from an Rv2386c protein selected from the group consisting of SEQ ID NOs: 1 and 6.

6. The method according to claim 5 , wherein the subject is a human.

7. The method according to claim 5 , wherein the subject has active tuberculosis.

8. The method according to claim 5 , wherein the subject has latent tuberculosis.

9. The method according to claim 5 , wherein the subject does not have tuberculosis.

10. The method according to claim 5 , wherein the immune response is a T-cell response.

11. The method according to claim 5 , for eliciting a T-cell response in a human subject comprising the administration of a polypeptide which comprises an immunogenic fragment of at least 20 contiguous amino acids from the Rv2386c protein of SEQ ID NO: 1.

12. The method according to claim 11 , wherein the subject has active tuberculosis.

13. The method according to claim 11 , wherein the subject has latent tuberculosis.

14. The method according to claim 11 , wherein the subject does not have tuberculosis.

15. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.

Assignees

• Glaxosmithkline Biologicals Sa
• Glaxo Group Ltd

Inventors

• Mettens Pascal
• Brown James
• Murphy Dennis

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/06

  for tuberculosis · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K16/1289

  Mycobacteriaceae (F) · CPC title